Successful Weaning and Explantation of the Heartmate II Left Ventricular Assist Device

Lamarche, Yoan; Kearns, Mark J.; Josan, Kiranbir; Bashir, Jamil; Ignaszewski, Andrew; Kaan, Annemarie; Kealy, J.; Moss, Robert; Cheung, Anson

doi:10.1016/j.cjca.2011.01.005

Cited by 45 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Utah Cardiac Recovery Program reported on 154 patients with chronic advanced dilated cardiomyopathy supported with a continuous flow left VAD (acute HF prospectively excluded by study design) and observed an improvement in left ventricular ejection fraction of ≥40% in 21% of patients with non-ischemic cardiomyopathy and 5% in those with ischemic cardiomyopathy [11]. Noteworthy, as evident in Table 1, these latter cardiac recovery results in ischemic and non-ischemic chronic dilated cardiomyopathy are consistent with earlier conclusions published by the Berlin, US LVAD Working Group, Montefiore, Gothenburg and Vancouver groups [8][9][10][11][12][13][14].…”

supporting

confidence: 80%

“…As a result, some patients placed on long-term MCS demonstrate reverse cardiac remodeling with restoration of cardiac function permitting weaning from the MCS device. Table 1 summarizes the results of key clinical outcome studies investigating cardiac functional and structural improvement following longterm MCS therapy (only prospective studies were included) [8][9][10][11][12][13][14][15][16][17][18][19][20]. The differences in cardiac recovery rates in these studies likely represents variability in study design, patient selection and differing acceptable thresholds of cardiac recovery to permit device explantation, as defined by the investigators.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute

Drakos

Pagani

Lundberg

et al. 2017

Journal of Cardiac Failure

View full text Add to dashboard Cite

supporting

confidence: 80%

mentioning

confidence: 99%

Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute

Drakos

Pagani

Lundberg

et al. 2017

Journal of Cardiac Failure

View full text Add to dashboard Cite

“…Although this is not a trial aimed at assessing recovery, close follow-up of these patients may shed a light on this issue. In general, ideal candidates are those with nonischemic cardiomyopathy, even though some studies have suggested that patients with ischemic HF can benefit [57]. Also, the selection of the device as well as mode of operation has not been studied well enough.…”

Section: Better Selectionmentioning

confidence: 97%

Myocardial recovery: a focus on the impact of left ventricular assist devices

Halbreiner

Cruz

Starling

et al. 2014

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Heart failure remains one of the most prevalent diseases worldwide and in recent decades, left ventricular assist devices (LVADs) have become an important treatment option. With increasing device experience, there is particular interest in the use of LVADs as a bridge to recovery that allows the patient's heart to undergo reverse remodeling, whereby the device can be explanted and the heart can function at an improved state. There are many considerations that play a role in this process, including the ability of the device to unload the heart, the innate physiology of the heart to recover and the use of concomitant therapies. This review provides an overview of the most current literature as it pertains to these processes and gives a view into the future directions of LVADs as a tool for achieving myocardial recovery.

show abstract

“…In fact, only 1% of devices placed in the most recent INTERMACS data were placed as bridge to recovery. Nevertheless, experience with weaning protocols and techniques is growing [27,28]. The possibility of recovery, although difficult to predict, favors the young and those with myocarditis as the impetus for device implantation [27].…”

Section: Myocardial Recovery and Explantationmentioning

confidence: 99%

Left ventricular assist devices in heart failure

Kilic

Ailawadi

2012

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

End-stage heart failure is an ever-growing and devastating disease. The median survival for patients with heart failure on ionotropic support alone is a meager 6 months. Historically, the only option for these patients was to be listed for heart transplantation. Out of medical necessity, the idea of left ventricular assist device (LVAD) as a bridge to transplantation was born. Since their approval by the US FDA, LVADs have quadrupled the survival in patients with heart failure. The increase in survival has also been accompanied by decreased perioperative morbidity, better biocompatibility and longer device life over first-generation LVADs. Undoubtedly, LVADs have changed the landscape of heart failure treatment and will continue to do so in the foreseeable future. In this review, we will highlight the landmark studies that have established LVADs as a therapeutic option for heart failure, as well as reviewing the current LVADs available and speculating on the advancements that will be made in the upcoming years.

show abstract

Successful Weaning and Explantation of the Heartmate II Left Ventricular Assist Device

Cited by 45 publications

References 19 publications

Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute

Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute

Myocardial recovery: a focus on the impact of left ventricular assist devices

Left ventricular assist devices in heart failure

Contact Info

Product

Resources

About